mouse igg2a monoclonal anti human icam 1 antibody  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC mouse igg2a monoclonal anti human icam 1 antibody
    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, <t>vehicle,</t> <t>ICAM-1,</t> RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).
    Mouse Igg2a Monoclonal Anti Human Icam 1 Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse igg2a monoclonal anti human icam 1 antibody/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse igg2a monoclonal anti human icam 1 antibody - by Bioz Stars, 2024-02
    86/100 stars

    Images

    1) Product Images from "Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19"

    Article Title: Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

    Journal: Nature Communications

    doi: 10.1038/s41467-023-37470-4

    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).
    Figure Legend Snippet: a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).

    Techniques Used: Western Blot, In Vitro, Cell Culture, Enzyme-linked Immunosorbent Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Infection, Immunoprecipitation, Co-Immunoprecipitation Assay

    mouse igg2a monoclonal anti human icam 1 antibody  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC mouse igg2a monoclonal anti human icam 1 antibody
    A) Experimental model overview. Primary air liquid interface (ALI)-differentiated human bronchial epithelial cells (HBECs) from control individuals and patients with asthma were treated with house dust mite (HDM) (200 μg/mL) or vehicle for 24h, followed by an infection with rhinovirus A16 (RV-A16) or UV-treated (UV)-RV-A16 in the multiplicity of infection (MOI) 0.1 for 24h. B) IL-1β release to the apical compartment assessed by ELISA (control n=14-22; asthma n=14-17). C) Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) from HBECs from control subjects (left panel) and patients with asthma (right panel) D) Representative confocal images of ASC speck formation in HBECs from patients with asthma (n=3); scale bars: 10μm. E) mRNA expression of IL1B (IL1β) was assessed using RT-PCR, and presented as a relative quantification (RQ=2 -ΔΔCt ) compared to the vehicle from the controls (control n=9-10, asthma n=8-10). F) Representative confocal images of IL-1β in HBECs from patients with asthma (n=3); scale bars: 10μm G) IL-1β release to the apical compartment assessed by ELISA (n=6-7), and H) mRNA expression of IL1B (IL1β) (n=3), in HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). Data are presented as the percentage of the response after HDM+RV-A16 treatment. I) IL-1β release to the apical supernatants assessed by ELISA (n=4), and J) mRNA expression of IL1B (IL1β) in HBECs (n=3) from patients with asthma in the presence or absence <t>of</t> <t>anti-ICAM-1</t> combined with HDM+RV-A16 stimulation. Data are presented as the percentage of the response after HDM+RV-A16 treatment. HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. (*) represents a significant difference as indicated. (#) represents a significant difference of the designated condition as compared to the vehicle from the same group. (&) represents a significant difference upon HDM treatment as compared to the corresponding condition without HDM. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal-Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model, as appropriate, depending on the data relation (paired or unpaired) and distribution, *p-value≤0.05, **p-value≤0.01, ***p-value≤0.001. ALI ; Air-liquid interface cultures; anti-ICAM-1 , anti-ICAM-1 antibody; IC ; Isotype control; HDM , house dust mite; RV-A16 , rhinovirus A16; UV-RV-A16 , UV-treated rhinovirus A16; YVAD , ac-YVAD-cmk (caspase-1 inhibitor); MOI , multiplicity of infection.
    Mouse Igg2a Monoclonal Anti Human Icam 1 Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse igg2a monoclonal anti human icam 1 antibody/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse igg2a monoclonal anti human icam 1 antibody - by Bioz Stars, 2024-02
    86/100 stars

    Images

    1) Product Images from "Epithelial RIG-I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus-induced asthma exacerbations and COVID-19"

    Article Title: Epithelial RIG-I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus-induced asthma exacerbations and COVID-19

    Journal: medRxiv

    doi: 10.1101/2021.11.16.21266115

    A) Experimental model overview. Primary air liquid interface (ALI)-differentiated human bronchial epithelial cells (HBECs) from control individuals and patients with asthma were treated with house dust mite (HDM) (200 μg/mL) or vehicle for 24h, followed by an infection with rhinovirus A16 (RV-A16) or UV-treated (UV)-RV-A16 in the multiplicity of infection (MOI) 0.1 for 24h. B) IL-1β release to the apical compartment assessed by ELISA (control n=14-22; asthma n=14-17). C) Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) from HBECs from control subjects (left panel) and patients with asthma (right panel) D) Representative confocal images of ASC speck formation in HBECs from patients with asthma (n=3); scale bars: 10μm. E) mRNA expression of IL1B (IL1β) was assessed using RT-PCR, and presented as a relative quantification (RQ=2 -ΔΔCt ) compared to the vehicle from the controls (control n=9-10, asthma n=8-10). F) Representative confocal images of IL-1β in HBECs from patients with asthma (n=3); scale bars: 10μm G) IL-1β release to the apical compartment assessed by ELISA (n=6-7), and H) mRNA expression of IL1B (IL1β) (n=3), in HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). Data are presented as the percentage of the response after HDM+RV-A16 treatment. I) IL-1β release to the apical supernatants assessed by ELISA (n=4), and J) mRNA expression of IL1B (IL1β) in HBECs (n=3) from patients with asthma in the presence or absence of anti-ICAM-1 combined with HDM+RV-A16 stimulation. Data are presented as the percentage of the response after HDM+RV-A16 treatment. HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. (*) represents a significant difference as indicated. (#) represents a significant difference of the designated condition as compared to the vehicle from the same group. (&) represents a significant difference upon HDM treatment as compared to the corresponding condition without HDM. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal-Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model, as appropriate, depending on the data relation (paired or unpaired) and distribution, *p-value≤0.05, **p-value≤0.01, ***p-value≤0.001. ALI ; Air-liquid interface cultures; anti-ICAM-1 , anti-ICAM-1 antibody; IC ; Isotype control; HDM , house dust mite; RV-A16 , rhinovirus A16; UV-RV-A16 , UV-treated rhinovirus A16; YVAD , ac-YVAD-cmk (caspase-1 inhibitor); MOI , multiplicity of infection.
    Figure Legend Snippet: A) Experimental model overview. Primary air liquid interface (ALI)-differentiated human bronchial epithelial cells (HBECs) from control individuals and patients with asthma were treated with house dust mite (HDM) (200 μg/mL) or vehicle for 24h, followed by an infection with rhinovirus A16 (RV-A16) or UV-treated (UV)-RV-A16 in the multiplicity of infection (MOI) 0.1 for 24h. B) IL-1β release to the apical compartment assessed by ELISA (control n=14-22; asthma n=14-17). C) Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) from HBECs from control subjects (left panel) and patients with asthma (right panel) D) Representative confocal images of ASC speck formation in HBECs from patients with asthma (n=3); scale bars: 10μm. E) mRNA expression of IL1B (IL1β) was assessed using RT-PCR, and presented as a relative quantification (RQ=2 -ΔΔCt ) compared to the vehicle from the controls (control n=9-10, asthma n=8-10). F) Representative confocal images of IL-1β in HBECs from patients with asthma (n=3); scale bars: 10μm G) IL-1β release to the apical compartment assessed by ELISA (n=6-7), and H) mRNA expression of IL1B (IL1β) (n=3), in HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). Data are presented as the percentage of the response after HDM+RV-A16 treatment. I) IL-1β release to the apical supernatants assessed by ELISA (n=4), and J) mRNA expression of IL1B (IL1β) in HBECs (n=3) from patients with asthma in the presence or absence of anti-ICAM-1 combined with HDM+RV-A16 stimulation. Data are presented as the percentage of the response after HDM+RV-A16 treatment. HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. (*) represents a significant difference as indicated. (#) represents a significant difference of the designated condition as compared to the vehicle from the same group. (&) represents a significant difference upon HDM treatment as compared to the corresponding condition without HDM. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal-Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model, as appropriate, depending on the data relation (paired or unpaired) and distribution, *p-value≤0.05, **p-value≤0.01, ***p-value≤0.001. ALI ; Air-liquid interface cultures; anti-ICAM-1 , anti-ICAM-1 antibody; IC ; Isotype control; HDM , house dust mite; RV-A16 , rhinovirus A16; UV-RV-A16 , UV-treated rhinovirus A16; YVAD , ac-YVAD-cmk (caspase-1 inhibitor); MOI , multiplicity of infection.

    Techniques Used: Infection, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction

    A) Detailed experimental in vitro model overview. Primary human bronchial epithelial cells (HBECs) from control individuals (blue) or patients with asthma (red) were differentiated for 21-28 days in the Air-Liquid Interface (ALI) culture. 24h prior rhinovirus A16 (RV-A16) infection, cells were stimulated with house dust mite (HDM) (200μg/mL) and/or caspase-1 inhibitor (YVAD), TBK1/IKKε inhibitor (BX795) and NLRP3 inflammasome inhibitor (MCC950) or vehicle. To block cell entry of RV-A16, HBECs were incubated with anti-ICAM-1 antibodies 3h before the infection. Cells were infected with RV-A16 at the multiplicity of infection (MOI) 0.1, 0.01 and 0.001 or the respective UV-RV-A16 controls. Protein, RNA, cells, and supernatants were harvested at 6h and 24h after infection. B-C) IL-1β release to the apical compartment was assessed by ELISA B) two independent HDM extracts, HDM (the main one used in the manuscript) and HDM B (similar extract from a different company), were tested 24h after RV-A16 infection (n=3); and C) for 6h (yellow) and 24h p.i. (red) (n=4). Data are presented as the percentage of the response after 24h p.i. D) IL-1β release to the apical compartment assessed by ELISA 24h after RV-A16 infection in the MOI 0.1, 0.01, and 0.001, combined with HDM pre-stimulation (n=4). Data are presented as the percentage of the response after RV-A16 infection in the MOI 0.1. E) expression of RV-A16 positive strand (RV-A16 viral RNA) was assessed using RT-PCR, and presented as the relative quantification (RQ=2 -ΔΔCt ) as compared to the vehicle condition in the HBECs from control individuals (control n=7, asthma n=7-9). F) Representative confocal images of ASC speck formation in the HBECs from control subjects (n=3); scale bars: 10μm. G) Quantification of ASC specks, presented as a number of specks (5-11 equal epithelial areas from control n=3, asthma n=3). H) Quantification of densitometry results of pro-IL-1β protein assessed by Western Blot, presented as a log-transformed ratio relative to β-actin and normalized to the vehicle condition in control individuals (control n=9, asthma n=8). I) IL-1β protein in the bronchoalveolar lavage (BAL) fluid of control subjects and patients with asthma (cohort SIBRO), assessed using the mesoscale platform and Welsh’s t-test. (control n=8, asthma n=12). J-K) Quantification of densitometry results from J) ASC and K) pro-caspase-1 protein expression assessed by Western Blot, presented as a log-transformed ratio relative to β-actin expression and normalized to the vehicle condition in the HBECs from the control individuals (ASC: control n=4, asthma n=4; caspase-1: control n=5, asthma n=5). L-M) expression of RV-A16 positive strand (RV-A16 viral RNA) in the HBECs from patients with asthma after L) YVAD treatment (n=3), and M) anti-ICAM-1 stimulation (n=3) was assessed using RT-PCR, and presented as a relative quantification (RQ=2 -ΔΔCt ) as compared to the vehicle condition from patients with asthma or control individuals . Data are presented as the percentage of the response after HDM+RV-A16 treatment. HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. (*) represents a significant difference as indicated. (#) represents a significant difference of indicated condition as compared to the vehicle from the same group. (&) represents a significant difference upon HDM treatment when compared to the respective condition without HDM. ($) represents a significant difference between RV-A16 and UV-RV-A16 condition. (+) represents a significant difference between HDM+RV-A16 and HDM condition. Bar graph data show mean ± SEM analysed with one- way ANOVA (Kruskal-Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model, as appropriate, depending on the data relation (paired or unpaired) and distribution (if not mentioned differently), *p- value≤0.05, **p-value≤0.01, ***p-value≤0.001, ****p-value≤0.0001. was prepared with Biorender.com. ALI ; Air-liquid interface cultures ; BAL ; Bronchoalveolar lavage, HBECs , differentiated human bronchial epithelial cells; HDM , house dust mite; RV-A16 , rhinovirus A16; UV-RV-A16 , UV-treated rhinovirus A16; YVAD , ac-YVAD-cmk (caspase-1 inhibitor); anti-ICAM-1 , anti-ICAM-1 antibody; BX795 , TBK1/IKKε inhibitor; MCC950 , NLRP3 inflammasome inhibitor; MOI , multiplicity of infection; p.i. , post-infection.
    Figure Legend Snippet: A) Detailed experimental in vitro model overview. Primary human bronchial epithelial cells (HBECs) from control individuals (blue) or patients with asthma (red) were differentiated for 21-28 days in the Air-Liquid Interface (ALI) culture. 24h prior rhinovirus A16 (RV-A16) infection, cells were stimulated with house dust mite (HDM) (200μg/mL) and/or caspase-1 inhibitor (YVAD), TBK1/IKKε inhibitor (BX795) and NLRP3 inflammasome inhibitor (MCC950) or vehicle. To block cell entry of RV-A16, HBECs were incubated with anti-ICAM-1 antibodies 3h before the infection. Cells were infected with RV-A16 at the multiplicity of infection (MOI) 0.1, 0.01 and 0.001 or the respective UV-RV-A16 controls. Protein, RNA, cells, and supernatants were harvested at 6h and 24h after infection. B-C) IL-1β release to the apical compartment was assessed by ELISA B) two independent HDM extracts, HDM (the main one used in the manuscript) and HDM B (similar extract from a different company), were tested 24h after RV-A16 infection (n=3); and C) for 6h (yellow) and 24h p.i. (red) (n=4). Data are presented as the percentage of the response after 24h p.i. D) IL-1β release to the apical compartment assessed by ELISA 24h after RV-A16 infection in the MOI 0.1, 0.01, and 0.001, combined with HDM pre-stimulation (n=4). Data are presented as the percentage of the response after RV-A16 infection in the MOI 0.1. E) expression of RV-A16 positive strand (RV-A16 viral RNA) was assessed using RT-PCR, and presented as the relative quantification (RQ=2 -ΔΔCt ) as compared to the vehicle condition in the HBECs from control individuals (control n=7, asthma n=7-9). F) Representative confocal images of ASC speck formation in the HBECs from control subjects (n=3); scale bars: 10μm. G) Quantification of ASC specks, presented as a number of specks (5-11 equal epithelial areas from control n=3, asthma n=3). H) Quantification of densitometry results of pro-IL-1β protein assessed by Western Blot, presented as a log-transformed ratio relative to β-actin and normalized to the vehicle condition in control individuals (control n=9, asthma n=8). I) IL-1β protein in the bronchoalveolar lavage (BAL) fluid of control subjects and patients with asthma (cohort SIBRO), assessed using the mesoscale platform and Welsh’s t-test. (control n=8, asthma n=12). J-K) Quantification of densitometry results from J) ASC and K) pro-caspase-1 protein expression assessed by Western Blot, presented as a log-transformed ratio relative to β-actin expression and normalized to the vehicle condition in the HBECs from the control individuals (ASC: control n=4, asthma n=4; caspase-1: control n=5, asthma n=5). L-M) expression of RV-A16 positive strand (RV-A16 viral RNA) in the HBECs from patients with asthma after L) YVAD treatment (n=3), and M) anti-ICAM-1 stimulation (n=3) was assessed using RT-PCR, and presented as a relative quantification (RQ=2 -ΔΔCt ) as compared to the vehicle condition from patients with asthma or control individuals . Data are presented as the percentage of the response after HDM+RV-A16 treatment. HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. (*) represents a significant difference as indicated. (#) represents a significant difference of indicated condition as compared to the vehicle from the same group. (&) represents a significant difference upon HDM treatment when compared to the respective condition without HDM. ($) represents a significant difference between RV-A16 and UV-RV-A16 condition. (+) represents a significant difference between HDM+RV-A16 and HDM condition. Bar graph data show mean ± SEM analysed with one- way ANOVA (Kruskal-Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model, as appropriate, depending on the data relation (paired or unpaired) and distribution (if not mentioned differently), *p- value≤0.05, **p-value≤0.01, ***p-value≤0.001, ****p-value≤0.0001. was prepared with Biorender.com. ALI ; Air-liquid interface cultures ; BAL ; Bronchoalveolar lavage, HBECs , differentiated human bronchial epithelial cells; HDM , house dust mite; RV-A16 , rhinovirus A16; UV-RV-A16 , UV-treated rhinovirus A16; YVAD , ac-YVAD-cmk (caspase-1 inhibitor); anti-ICAM-1 , anti-ICAM-1 antibody; BX795 , TBK1/IKKε inhibitor; MCC950 , NLRP3 inflammasome inhibitor; MOI , multiplicity of infection; p.i. , post-infection.

    Techniques Used: In Vitro, Infection, Blocking Assay, Incubation, Enzyme-linked Immunosorbent Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Transformation Assay

    mouse monoclonal igg against human icam 1  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC mouse monoclonal igg against human icam 1
    Mouse Monoclonal Igg Against Human Icam 1, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal igg against human icam 1/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal igg against human icam 1 - by Bioz Stars, 2024-02
    86/100 stars

    Images

    mouse anti human monoclonal icam 1 igg  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC mouse anti human monoclonal icam 1 igg
    Mouse Anti Human Monoclonal Icam 1 Igg, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human monoclonal icam 1 igg/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human monoclonal icam 1 igg - by Bioz Stars, 2024-02
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    ATCC mouse igg2a monoclonal anti human icam 1 antibody
    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, <t>vehicle,</t> <t>ICAM-1,</t> RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).
    Mouse Igg2a Monoclonal Anti Human Icam 1 Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse igg2a monoclonal anti human icam 1 antibody/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse igg2a monoclonal anti human icam 1 antibody - by Bioz Stars, 2024-02
    86/100 stars
      Buy from Supplier

    86
    ATCC mouse monoclonal igg against human icam 1
    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, <t>vehicle,</t> <t>ICAM-1,</t> RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).
    Mouse Monoclonal Igg Against Human Icam 1, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal igg against human icam 1/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal igg against human icam 1 - by Bioz Stars, 2024-02
    86/100 stars
      Buy from Supplier

    86
    ATCC mouse anti human monoclonal icam 1 igg
    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, <t>vehicle,</t> <t>ICAM-1,</t> RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).
    Mouse Anti Human Monoclonal Icam 1 Igg, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human monoclonal icam 1 igg/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human monoclonal icam 1 igg - by Bioz Stars, 2024-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).

    Journal: Nature Communications

    Article Title: Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

    doi: 10.1038/s41467-023-37470-4

    Figure Lengend Snippet: a Representative Western Blot images of secreted IL-1β (apical compartment), and pro-IL-1β, ASC, pro-caspase-1 and β-actin (cell lysates) in in vitro-cultured HBECs from control subjects ( n = 3, left panel) and patients with asthma ( n = 3, right panel). b IL-1β release to the apical compartment assessed by ELISA in in vitro-cultured HBECs from control ( n = 22, vehicle; n = 14, UV-RV-A16; n = 23, RV-A16) and asthma ( n = 17, vehicle; n = 14, UV-RV-A16; n = 18, RV-A16). c Representative confocal images of ASC speck formation in in vitro-cultured HBECs from control individuals and patients with asthma (control n = 3, asthma n = 3); scale bars: 10 μm. d Quantification of ASC specks, presented as a number of specks (mean from 5–11 equal epithelial areas from two/three technical replicates from control n = 3, asthma n = 3). e IL-1β release to the apical compartment assessed by ELISA ( n = 6, HDM; n = 7, HDM + RV-A16, HDM + RV-A16 + YVAD) in in vitro-cultured HBECs from patients with asthma in the presence or absence of caspase-1 inhibitor (YVAD). f Expression of RV-A16 positive strand (RV-A16 viral RNA) in in vitro-cultured HBECs from patients with asthma and controls ( n = 16, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 8, UV-RV-A16) after anti-ICAM-1 treatment was assessed using RT-PCR and presented as a relative quantification (RQ = 2 -ΔΔCt ) as compared to the vehicle condition. g IL-1β release to the apical supernatants assessed by ELISA in in vitro–cultured HBECs from patients with asthma and healthy controls ( n = 10, vehicle, ICAM-1, RV-A16, RV-A16 + ICAM-1; n = 3, UV-RV-A16) in the presence or absence of anti-ICAM-1 combined with RV-A16 infection. e-g Data are presented as the percentage of the response after in vitro RV-A16 treatment. h Representative Western Blot images of RIG-I protein expression in in vitro-cultured HBECs from patients with asthma ( n = 4). i Representative confocal images of RIG-I in in vitro-cultured HBECs from patients with asthma ( n = 3); scale bars: 10 μm. j Co-immunoprecipitation (co-IP) of ASC/RIG-I complex using anti-ASC antibodies followed by RIG-I detection in the presence of HDM in in vitro-cultured HBECs from patients with asthma ( n = 4). k Co-immunoprecipitation (co-IP) of ASC/MDA5 complex using anti-ASC antibodies followed by MDA5 detection in in vitro-cultured HBECs from patients with asthma ( n = 3). l Representative Western Blot images of NLRP3 protein in in vitro-cultured HBECs from patients with asthma ( n = 4). m Representative confocal images of NLRP3 and Occludin in vitro-cultured HBECs from patients with asthma in the presence of HDM ( n = 3), scale bars: 10 μm. n IL-1β release to the apical compartment in in-vitro-cultured HBECs with/without RV-A16 and NLRP3 inflammasome inhibitor (MCC950) (control n = 3, asthma n = 3). HBECs from patients with asthma are presented in red, HBECs from control individuals are presented in blue. ( n ) indicates the number of biologically independent samples examined over at least three independent experiments. Bar graph data show mean ± SEM analyzed with one-way ANOVA (Kruskal–Wallis test), RM one-way ANOVA (Friedman test) or mixed-effects model with post-hoc analysis, as appropriate, depending on the data relation (paired or unpaired) and distribution. Source data are provided as Source Data files. anti-ICAM-1 , anti-ICAM-1 antibody; Co-IP Co-immunoprecipitation, HBECs human bronchial epithelial cells, HDM house dust mite, IC Isotype control, IP Ab antibodies used for co-precipitation, MCC950 , NLRP3 inflammasome inhibitor; RV-A16 rhinovirus A16; UV-RV-A16 UV-treated rhinovirus A16; YVAD YVAD- (caspase-1 inhibitor).

    Article Snippet: Mouse IgG2a monoclonal anti-human ICAM-1 antibody (antibody R6.5) was produced from the hybridoma cells (ATCC HB-9580, mouse hybridoma).

    Techniques: Western Blot, In Vitro, Cell Culture, Enzyme-linked Immunosorbent Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Infection, Immunoprecipitation, Co-Immunoprecipitation Assay